SNHP | Nurse Anesthesia DNP Project Presentations
Academic Level at Time of Presentation
Graduate
Major
DNP
List all Project Mentors & Advisor(s)
Dr. Kristin Reid
Presentation Format
Poster Presentation
Abstract/Description
Abstract
Purpose: Postoperative nausea and vomiting (PONV) affect a significant number of surgical patients. This Doctor of Nursing Practice project aimed to assess PONV rates and evaluate the effects of dexmedetomidine on PONV incidence in intraabdominal surgical patients. Additionally, the project sought to inform Certified Registered Nurse Anesthetists (CRNAs) about dexmedetomidine and assess the perceived value of this information through a survey.
Methodology: The retrospective analysis of 9,035 patients was conducted from January 2023 to July 2024. Data were divided into four datasets, and comparisons were made between the datasets to determine PONV rates and the effects of dexmedetomidine. The survey results from the CRNAs were collected and analyzed.
Results: A statistically significant difference was found between patients who received dexmedetomidine and those who did not. However, dexmedetomidine did not reduce PONV incidence. Survey responses indicated CRNAs found the information valuable, but its dissemination did not significantly increase dexmedetomidine use.
Conclusion: Despite PONV rates generally ranging from 30% -80% (Elvir-Lazo et al., 2022), the facility’s rates remained below 30%. Dexmedetomidine administration did not decrease PONV, nor did information on its use influence its administration rates.
The Effects of Dexmedetomidine on Nausea and Vomiting in Intraabdominal Surgical Patients
Abstract
Purpose: Postoperative nausea and vomiting (PONV) affect a significant number of surgical patients. This Doctor of Nursing Practice project aimed to assess PONV rates and evaluate the effects of dexmedetomidine on PONV incidence in intraabdominal surgical patients. Additionally, the project sought to inform Certified Registered Nurse Anesthetists (CRNAs) about dexmedetomidine and assess the perceived value of this information through a survey.
Methodology: The retrospective analysis of 9,035 patients was conducted from January 2023 to July 2024. Data were divided into four datasets, and comparisons were made between the datasets to determine PONV rates and the effects of dexmedetomidine. The survey results from the CRNAs were collected and analyzed.
Results: A statistically significant difference was found between patients who received dexmedetomidine and those who did not. However, dexmedetomidine did not reduce PONV incidence. Survey responses indicated CRNAs found the information valuable, but its dissemination did not significantly increase dexmedetomidine use.
Conclusion: Despite PONV rates generally ranging from 30% -80% (Elvir-Lazo et al., 2022), the facility’s rates remained below 30%. Dexmedetomidine administration did not decrease PONV, nor did information on its use influence its administration rates.
